Education
About Us
Working with TipRanks
Follow Us
Esperion Therapeutics (ESPR)
:ESPR
ESPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.57 - $3.94
Previous CloseN/A
Volume1.55M
Average Volume (3M)3.62M
Market Cap
$334.96M
Enterprise Value$736.50M
Total Cash (Recent Filing)$36.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.15
Next Earnings
Mar 04, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding197,035,170
10 Day Avg. Volume2,808,741
30 Day Avg. Volume3,619,779
Standard Deviation0.27
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.13
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap2.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.08
Enterprise Value/Ebitda-25.53
Forecast
1Y Price Target
$6.76Price Target Upside327.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Esperion News
PremiumCompany Announcements
Esperion Therapeutics Reports Strong Revenue Growth in 2024
PremiumCompany Announcements
Esperion Therapeutics’ Earnings Call: Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Global ExpansionEsperion secures another key deal to broaden global reach.
Product EfficacyEsperion presented additional exploratory data demonstrating the impact of bempedoic acid on reducing major adverse limb events in patients with peripheral artery disease.
Bears Say
Financial ProjectionsThe U.S. sales projection is lowered from $286MM to approximately $196MM, aligning with the consensus estimate.
---
Ownership Overview
0.99% Insiders
18.47% Mutual Funds
27.56% Other Institutional Investors
43.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion Therapeutics’s price range in the past 12 months?
Esperion Therapeutics lowest stock price was $1.57 and its highest was $3.94 in the past 12 months.
What is Esperion Therapeutics’s market cap?
Esperion Therapeutics’s market cap is $334.96M.
When is Esperion Therapeutics’s upcoming earnings report date?
Esperion Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is yesterday.
How were Esperion Therapeutics’s earnings last quarter?
Esperion Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.025.
Is Esperion Therapeutics overvalued?
According to Wall Street analysts Esperion Therapeutics’s price is currently Undervalued.
Does Esperion Therapeutics pay dividends?
Esperion Therapeutics does not currently pay dividends.
What is Esperion Therapeutics’s EPS estimate?
Esperion Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Esperion Therapeutics have?
Esperion Therapeutics has 197,035,170 shares outstanding.
What happened to Esperion Therapeutics’s price movement after its last earnings report?
Esperion Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went down -4.525%.
Which hedge fund is a major shareholder of Esperion Therapeutics?
Currently, no hedge funds are holding shares in ESPR
---
Esperion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.76 (327.85% Upside)
$6.76 (327.85% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $44.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.03%
12-Months-Change
Fundamentals
Return on Equity
23.44%
Trailing 12-Months
Asset Growth
41.94%
Trailing 12-Months
Company Description
Esperion Therapeutics
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
ESPR Company Deck
---
ESPR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Esperion has shown strong prescription growth and expanded payer access, both domestically and internationally. While facing some financial headwinds due to contract updates, the company is on track for future growth with a strengthened financial position.Read More>---
ESPR Stock 12 Month Forecast
Average Price Target
$6.76
▲(327.85% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
9/24 ratings generated profit
1 Year Average Return
+37.86%
reiterated a buy rating last month
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +37.86% per trade.
---